NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%
NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%

Ashoka Buildcon's Q4FY26/FY26 Performance Disappoints, But Management Sees Recovery in FY27

Ashoka Buildcon's research report by Prabhudas Lilladher has revealed a subdued performance in the company's Q4FY26/FY26, with standalone revenue declining by 10% year-over-year (YoY) and 18% YoY. This decline can be attributed to slower execution, which management expects to normalize in the coming year. The research report also highlights the company's expectations for a recovery in FY27, with around 20% revenue growth and EBITDA margins improving to 9.5-10.5%.

MetricQ4FY26/FY26FY27E
Revenue Growth-10% YoY~20%
EBITDA Margin-~9.5-10.5%

The company's FY26 order inflow stood at INR 66 billion, while its order book remains diversified at around INR 153 billion, equivalent to 2.6 times the trailing twelve months (TTM) revenue. This diversified order book provides medium-term revenue visibility, with around 66% exposure to roads and railways, and 20% to power transmission and distribution (T&D).

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

In order to strengthen its balance sheet, Ashoka Buildcon is expected to complete its highway asset monetization (HAM) program, which is expected to generate INR 11-12 billion in proceeds. This amount is sufficient to materially reduce the company's standalone debt, which currently stands at around INR 11 billion.

Outlook and Recommendations

Following the weak Q4 results, Prabhudas Lilladher has cut FY27E/FY28E earnings per share (EPS) estimates by 11% and 5%, respectively. Additionally, the target price (TP) has been lowered to INR 152. Despite near-term execution challenges, the research firm retains a BUY rating on the stock, citing its valuation support due to the company trading below book value.

Investor Takeaway

Investors should be cautious and monitor the company's recovery in FY27.

IPOScanner Logo

IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.

About IPO Scanner

IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.

Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.

Details of client bank account
For any query / feedback / clarifications, email at
[email protected].

Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.

© 2026 IPO Scanner. All rights reserved.